Skip to main content

A double-labeled probe for molecular imaging

Ref-Nr: TA-P-1124


Kurzfassung

The technology allows for direct and indirect detection of cancer tissue. It deals with a pharmaceutical compound consisting of three subdomains: (A) for specific cell surface binding to neoplastic cells, (B) for binding radiometals via a chelator domain for e.g. PET, and (C) harboring a fluorescent dye moiety for optical detection. The combination of PET tracer and optical moiety enables the surgeon to localize the tumor preoperatively via PET/CT and intraoperatively through optical detection.


Hintergrund

In recent years, molecular imaging has become increasingly important in the diagnosis of cancer. When using positron emission tomography/computed tomography (PET/CT) as a molecular imaging entity, the surgeon has to assess the size, localization and shape of the tumor obtained by PET/CT by mentally projecting the PET/CT image onto the patient’s body. This procedure has the major drawback that the surgeon can never be entirely sure to have removed the entire neoplastic tissue or the correct malignant lymph node. Therefore, fairly substantial parts of the tissue are often removed, including large amounts of healthy tissue, since remnants of neoplastic tissue might otherwise still remain in the patient.

The presented technology provides a pharmaceutical compound consisting of three subdomains:

(A) for specific cell surface binding to neoplastic cells,

(B) for binding radiometals via a chelator domain for e.g. PET, and

(C) harboring a fluorescent dye moiety for optical detection.

The combination of PET tracer and optical moiety enables the surgeon to localize the tumor preoperatively (via PET/CT) and intraoperatively (through optical detection), thus ensuring complete, but sparing, removal of the neoplastic tissue.  


Bilder & Videos


Problemstellung

Removing substantial parts of the tissue , including large amounts of healthy tissue, by using positron emission tomography/computed tomography (PET/CT).


Lösung

Complete, but sparing, removal of the neoplastic tissue by using the combination of PET tracer and optical moiety.


Vorteile

Compound binding specifically to PSMA-expressing prostate cancer cells and combining a PET chelator domain and a fluorescent dye domain for intraoperative detection of neoplastic tissue. 


Anwendungsbereiche

The current technology can be used for pre- and intraoperative detection of prostate cancer. 


Deutsches Krebsforschungszentrum DKFZ

Dr. Frieder Kern
+49-6221-42-2952
f.kern@dkfz.de
www.dkfz.de
Adresse
Im Neuenheimer Feld 280
69120 Heidelberg



Entwicklungsstand

Machbarkeit


Stichworte

Diagnostics

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr